Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006204 · ClinicalTrials.gov registry record · Phase 4
Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)
A Phase 4 study of Depression and Alcoholism, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- Completed
- Registry status
- Phase 4
- Development phase
- 106
- Enrollment target
- 1
- Study location
NCT00006204: Completed Phase 4 study of Depression and Alcoholism, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
NCT00006204 is a Phase 4 study of Depression and Alcoholism that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 106 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006204, a Phase 4 study of Depression and Alcoholism, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 106 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the effects of combing naltrexone and fluoxetine (Prozac) versus fluoxetine and placebo in alcoholics with co-occurring major depression. Both groups will actively participate in the 6-month study, which includes weekly individual Dual Disorders Recovery Counseling during the first month and every two weeks during the second through sixth months, plus the naltrexone and fluoxetine or fluoxetine and placebo. Subjects will complete follow-up assessments at 9 and 12 months.
Conditions Studied
Interventions
- DRUG naltrexone (Revia)
- DRUG fluoxetine (Prozac)
Study Locations (1)
Pennsylvania
- Department of Psychiatry, Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2000-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 4 |
What the finished NCT00006204 record still lists
NCT00006204 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower).
The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which naltrexone (Revia) is the first listed.
NCT00006204 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00006204 about?
NCT00006204 is a clinical study titled "Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)". This study will examine the effects of combing naltrexone and fluoxetine (Prozac) versus fluoxetine and placebo in alcoholics with co-occurring major depression. Both groups will actively participate in the 6-month study, which includes weekly individual Dual Disorders Recovery Counseling during the...
What is the current status of trial NCT00006204?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 106 participants. The study started on 2000-03. Estimated completion is 2006-01.
What conditions does trial NCT00006204 study?
This clinical trial studies the following conditions: Depression, Alcoholism, Alcohol Dependence.
What interventions are being tested in trial NCT00006204?
The interventions under investigation include: naltrexone (Revia) (DRUG), fluoxetine (Prozac) (DRUG).
Who is sponsoring clinical trial NCT00006204?
This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006204 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006204's enrollment target sits among peer trials
106 317th of 679 higher than 361 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03181048 · 106 participants · NA
Clinical Trial of Concomitant Hip Arthroscopy During PAO
- NCT04682158 · 106 participants · Phase 2
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
- NCT04724018 · 106 participants · Phase 1
Sacituzumab Govitecan Plus EV in Metastatic UC
- NCT04798274 · 106 participants · NA
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia